ECSP034658A - Combinacion terapeutica de amlodipina y benazepril/benazeprilato - Google Patents
Combinacion terapeutica de amlodipina y benazepril/benazeprilatoInfo
- Publication number
- ECSP034658A ECSP034658A EC2003004658A ECSP034658A ECSP034658A EC SP034658 A ECSP034658 A EC SP034658A EC 2003004658 A EC2003004658 A EC 2003004658A EC SP034658 A ECSP034658 A EC SP034658A EC SP034658 A ECSP034658 A EC SP034658A
- Authority
- EC
- Ecuador
- Prior art keywords
- milligrams
- pharmaceutically acceptable
- benazepril
- angiotesin
- corresponds
- Prior art date
Links
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title abstract 2
- 229960004530 benazepril Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- 229960003619 benazepril hydrochloride Drugs 0.000 abstract 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 abstract 1
- 229960004067 benazeprilat Drugs 0.000 abstract 1
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere en especial al uso de una combinación que comprende: (1) un inhibidor de la enzima convertidora de angiotesina, seleccionado a partir del grupo que consiste en benazepril, benazeprilato, y sales farmacéuticamente aceptables de los mismos, y (2) amlodipina o una sal farmacéuticamente aceptable de la misma, para la fabricación de un medicamento para el tratamiento o la prevención o demora de progreso de una condición seleccionada a partir del grupo que consiste en hipertensión, insuficiencia cardíaca congestiva, angina, infarto de miocardia, asteriosclerosis, nefropatía diabética, mioatía cardíaca diabética, insuficiencia renal, vasculopatía periférica, hipertrofía ventricular izquierda, disfunción cognoscitiva, cerebrovasculopatía relacionada con la presión sanguinea, embolia, enfermedad pulmonar, y dolor de cabeza; en donde: (i) la cantidad de amplodipina o una sal farmaceúticamente aceptable de la misma, corresponde a de aproximadamente 6 miligramos a aproximadamente 40 miligramos de la base libre y (ii) la cantidad del inhibidor de la enzima convertidora de angiotesina o una sal farmacéuticamente aceptable del mismo, corresponde a de aproximadamente 20 miligramos a aproximadamente 160 miligramos de clorhidrato de benazepril
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/034246 WO2002049645A1 (en) | 2000-12-18 | 2000-12-18 | Therapeutic combination of amlodipine and benazepril |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034658A true ECSP034658A (es) | 2003-07-25 |
Family
ID=21742073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004658A ECSP034658A (es) | 2000-12-18 | 2003-06-17 | Combinacion terapeutica de amlodipina y benazepril/benazeprilato |
Country Status (27)
| Country | Link |
|---|---|
| EP (3) | EP1365761A1 (es) |
| JP (3) | JP2004516266A (es) |
| KR (3) | KR20040007420A (es) |
| CN (2) | CN1461218A (es) |
| AT (1) | ATE338549T1 (es) |
| AU (4) | AU2581601A (es) |
| BR (2) | BR0017386A (es) |
| CA (2) | CA2432638A1 (es) |
| CY (1) | CY1106275T1 (es) |
| CZ (2) | CZ20031678A3 (es) |
| DE (1) | DE60122928T2 (es) |
| DK (1) | DK1345607T3 (es) |
| EC (1) | ECSP034658A (es) |
| ES (1) | ES2272565T3 (es) |
| HK (1) | HK1059566A1 (es) |
| HU (2) | HUP0302455A3 (es) |
| IL (4) | IL156136A0 (es) |
| MX (2) | MXPA03005462A (es) |
| NO (2) | NO20032765L (es) |
| NZ (1) | NZ526467A (es) |
| PL (2) | PL362252A1 (es) |
| PT (1) | PT1345607E (es) |
| RU (1) | RU2292206C2 (es) |
| SI (1) | SI1345607T1 (es) |
| SK (2) | SK7652003A3 (es) |
| WO (2) | WO2002049645A1 (es) |
| ZA (1) | ZA200304514B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1450793A2 (de) * | 2001-11-23 | 2004-09-01 | Solvay Pharmaceuticals GmbH | Hypertoniebehandlung während der akuten phase des schlaganfalls |
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| WO2004096228A1 (en) | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| EP1776115A2 (en) * | 2003-10-20 | 2007-04-25 | Novartis AG | Use of organic compounds |
| WO2005074927A1 (en) * | 2004-02-09 | 2005-08-18 | Novartis Ag | Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension |
| WO2005079772A2 (en) * | 2004-02-18 | 2005-09-01 | Sepracor Inc. | Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| WO2006085208A2 (en) * | 2005-02-11 | 2006-08-17 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine and benazepril |
| WO2006092732A2 (en) * | 2005-03-04 | 2006-09-08 | Aurobindo Pharma Ltd | Stable solid dosage form of antihypertensive agent |
| US10130624B2 (en) | 2005-03-15 | 2018-11-20 | Lupin Limited | Pharmaceutical compositions of amlodipine and benazepril |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| CA2620018A1 (en) * | 2005-09-28 | 2007-04-12 | Mali Kadosh | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| EP1930008A1 (en) * | 2005-09-28 | 2008-06-11 | Teva Pharmaceutical Industries Ltd | Sable composition of benazepril hydrochloride |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| SE534111C2 (sv) * | 2009-09-14 | 2011-05-03 | Scania Cv Ab | Metod och system för styrning av en koppling |
| IT1398168B1 (it) * | 2010-02-16 | 2013-02-14 | Chiesi Farma Spa | Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete. |
| WO2011161223A2 (en) | 2010-06-23 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| CN102389431A (zh) * | 2011-09-28 | 2012-03-28 | 济南龙华医药技术有限公司 | 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用 |
| RS54475B1 (en) | 2011-12-21 | 2016-06-30 | Novartis Tiergesundheit Ag | NEW COMBINATION |
| EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| US20150218103A1 (en) * | 2012-08-25 | 2015-08-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
| MX2016000727A (es) | 2013-07-19 | 2016-04-13 | Boehringer Ingelheim Vetmed | Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante. |
| HUE056143T2 (hu) | 2013-12-04 | 2024-01-28 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendán javított gyógyászati készítményei |
| CA3015964C (en) * | 2016-03-24 | 2021-08-03 | Daiichi Sankyo Company, Limited | Medicine for treating renal disease |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| KR20190085046A (ko) | 2016-11-16 | 2019-07-17 | 어바이드 테라퓨틱스, 인크. | 약학 제제 |
| CN115093382A (zh) | 2016-11-16 | 2022-09-23 | H.隆德贝克有限公司 | Magl抑制剂的结晶形式 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| JPH11503139A (ja) * | 1995-04-07 | 1999-03-23 | ノバルティス・アクチエンゲゼルシャフト | ベナゼプリルまたはベナゼプリラートおよびバルサルタンを含有する組み合わせ組成物 |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
-
2000
- 2000-12-18 BR BR0017386-0A patent/BR0017386A/pt not_active Application Discontinuation
- 2000-12-18 SK SK765-2003A patent/SK7652003A3/sk not_active Application Discontinuation
- 2000-12-18 PL PL00362252A patent/PL362252A1/xx not_active Application Discontinuation
- 2000-12-18 CA CA002432638A patent/CA2432638A1/en not_active Abandoned
- 2000-12-18 WO PCT/US2000/034246 patent/WO2002049645A1/en not_active Application Discontinuation
- 2000-12-18 KR KR10-2003-7007578A patent/KR20040007420A/ko not_active Application Discontinuation
- 2000-12-18 AU AU2581601A patent/AU2581601A/xx active Pending
- 2000-12-18 EP EP00989288A patent/EP1365761A1/en not_active Withdrawn
- 2000-12-18 JP JP2002550985A patent/JP2004516266A/ja active Pending
- 2000-12-18 CZ CZ20031678A patent/CZ20031678A3/cs unknown
- 2000-12-18 MX MXPA03005462A patent/MXPA03005462A/es not_active Application Discontinuation
- 2000-12-18 HU HU0302455A patent/HUP0302455A3/hu unknown
- 2000-12-18 IL IL15613600A patent/IL156136A0/xx unknown
- 2000-12-18 AU AU2001225816A patent/AU2001225816B2/en not_active Ceased
- 2000-12-18 CN CN00820080A patent/CN1461218A/zh active Pending
-
2001
- 2001-12-17 NZ NZ526467A patent/NZ526467A/en unknown
- 2001-12-17 DK DK01992150T patent/DK1345607T3/da active
- 2001-12-17 AU AU3262002A patent/AU3262002A/xx active Pending
- 2001-12-17 CZ CZ20031677A patent/CZ301424B6/cs not_active IP Right Cessation
- 2001-12-17 IL IL15626701A patent/IL156267A0/xx unknown
- 2001-12-17 SI SI200130662T patent/SI1345607T1/sl unknown
- 2001-12-17 PL PL01360989A patent/PL360989A1/xx not_active Application Discontinuation
- 2001-12-17 EP EP01992150A patent/EP1345607B1/en not_active Revoked
- 2001-12-17 EP EP06003150A patent/EP1674099A1/en not_active Withdrawn
- 2001-12-17 AU AU2002232620A patent/AU2002232620B9/en not_active Ceased
- 2001-12-17 CN CNA018208398A patent/CN1481241A/zh active Pending
- 2001-12-17 WO PCT/US2001/048808 patent/WO2002049646A1/en active Application Filing
- 2001-12-17 KR KR10-2003-7007754A patent/KR20030061840A/ko active Application Filing
- 2001-12-17 HU HU0302456A patent/HUP0302456A3/hu unknown
- 2001-12-17 ES ES01992150T patent/ES2272565T3/es not_active Expired - Lifetime
- 2001-12-17 DE DE60122928T patent/DE60122928T2/de not_active Revoked
- 2001-12-17 AT AT01992150T patent/ATE338549T1/de active
- 2001-12-17 MX MXPA03005463A patent/MXPA03005463A/es active IP Right Grant
- 2001-12-17 BR BR0116228-4A patent/BR0116228A/pt not_active IP Right Cessation
- 2001-12-17 SK SK764-2003A patent/SK7642003A3/sk not_active Application Discontinuation
- 2001-12-17 JP JP2002550986A patent/JP2004519440A/ja not_active Withdrawn
- 2001-12-17 RU RU2003121019/15A patent/RU2292206C2/ru not_active IP Right Cessation
- 2001-12-17 CA CA002432282A patent/CA2432282A1/en not_active Abandoned
- 2001-12-17 KR KR1020097004242A patent/KR20090033914A/ko not_active Application Discontinuation
- 2001-12-17 PT PT01992150T patent/PT1345607E/pt unknown
-
2003
- 2003-06-10 ZA ZA200304514A patent/ZA200304514B/xx unknown
- 2003-06-17 EC EC2003004658A patent/ECSP034658A/es unknown
- 2003-06-17 NO NO20032765A patent/NO20032765L/no not_active Application Discontinuation
- 2003-06-17 NO NO20032766A patent/NO20032766L/no not_active Application Discontinuation
-
2004
- 2004-02-11 HK HK04100922A patent/HK1059566A1/xx not_active IP Right Cessation
-
2006
- 2006-11-30 CY CY20061101728T patent/CY1106275T1/el unknown
-
2008
- 2008-04-10 IL IL190801A patent/IL190801A0/en unknown
- 2008-04-10 IL IL190802A patent/IL190802A0/en unknown
-
2009
- 2009-10-09 JP JP2009235225A patent/JP2010043111A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034658A (es) | Combinacion terapeutica de amlodipina y benazepril/benazeprilato | |
| JP2005532330A (ja) | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ | |
| CO6251256A2 (es) | Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4il)1h-pirazol-1-il)-3-ciclopentilpropanitrilo | |
| CR7074A (es) | Derivados de mercaptoacetylamida y proceso para su preparacion y uso | |
| EA009983B1 (ru) | Лекарственное средство для профилактики и лечения артериосклероза и гипертензии | |
| Märki et al. | Piperidine renin inhibitors: from leads to drug candidates | |
| PT1487424E (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii | |
| KR19980086748A (ko) | 당뇨성 심근증의 예방 또는 전환에 있어서 알도스 리덕타제의 억제 방법 | |
| BR0108592A (pt) | Compostos de piperazina substituìda | |
| US5798357A (en) | Agent for prophylaxis and treatment of thromboxane A2 -mediated diseases | |
| Opie | Calcium channel antagonists part III: use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications | |
| SG153644A1 (en) | Therapeutic combination of amlodipine and benazepril | |
| ES2263009T3 (es) | Citalopram para el tratamiento de la presion sanguinea elevada. | |
| Beręsewicz et al. | Effect of calmodulin antagonists on hypoxia and reoxygenation damage in isolated rabbit hearts | |
| Landau et al. | Calcium antagonists for the treatment of congestive heart failure | |
| Monopoli et al. | Effects of antihypertensive drugs on cardiac hypertrophy | |
| Makwana et al. | A SHORT REVIEW ON ANGINA PECTORIS | |
| KR20050016452A (ko) | Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물 | |
| RU2003121016A (ru) | Терапевтическая комбинация амлодипина и беназеприла | |
| Mealy et al. | Nolomirole Hydrochloride | |
| Ebner et al. | Clinical differentiation of nifedipine and other calcium antagonists. | |
| ZA200406066B (en) | Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ace inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for prolonging lifespan. |